Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mifepristone+ fluvastatin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| mifepristone + fluvastatin | DRUG | Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14). |
Inclusion Criteria: * Male or female healthy volunteers * Body mass index (BMI) of 18-32 kg/m2 * Female subjects must have a negative serum pregnancy test result prior to entry into the study * All female subjects must not be of child-bearing potential * All male subjects with female partners of ch...
Mifepristone is being developed by Corcept Therapeutics for Cushing's Syndrome, Cushing's Disease, and Major Depressive Disorder. It is a small molecule in Phase 3 clinical development for these endocrine and psychiatric conditions. The drug is investigational and has not been approved for these indications.
Corcept Therapeutics Incorporated (NASDAQ: CORT) is developing Mifepristone. The company is conducting clinical trials for the drug in indications including Cushing's Syndrome, Cushing's Disease, and Major Depressive Disorder. Corcept Therapeutics is the developer of this investigational small molecule.
Mifepristone is in Phase 3 clinical development for Cushing's Syndrome, Cushing's Disease, and Major Depressive Disorder. The drug is investigational and has not been approved by regulatory authorities for these indications. Corcept Therapeutics is conducting the clinical development program.
Mifepristone has completed five clinical trials. These include NCT00455442, a Phase 2 study in weight-gain prevention; NCT00698022, a Phase 1 study in healthy volunteers; NCT03258372 and NCT03259542, Phase 1 drug-drug interaction studies; and one additional completed trial. All trials are completed with no active studies ongoing.
Mifepristone is a small molecule that acts as a glucocorticoid receptor antagonist. By blocking the glucocorticoid receptor, it is being studied for its effects in Cushing's Syndrome, Cushing's Disease, and Major Depressive Disorder. This mechanism is relevant to conditions involving cortisol dysregulation.
Mifepristone is the active ingredient in Korlym, a medication approved for Cushing's syndrome. However, the data provided does not specify whether the Mifepristone in development by Corcept Therapeutics is the same product as Korlym. The drug is being studied in Phase 3 trials for related indications.